Diabeloop and ViCentra Announce European Distribution Partnership

Diabeloop comprehensive and personalized system integrates Kaleido
patch pump for autonomous type 1 diabetes management

Paris (ots/PRNewswire) - ViCentra, the company behind the Kaleido
insulin pump, and Diabeloop are announcing that they are entering
into a mutual distribution agreement for selected European countries.

Following successful clinical studies using ViCentra's Kaleido
micro insulin pump, Diabeloop's DBLG1 obtained CE marking in November
2018. With this distribution agreement the combined DBLG1 System will
become commercially available in selected European countries.

The DBLG1 System, also integrating continuous glucose monitor
(CGM) Dexcom G6, calculates the amount of insulin required and
automatically adjusts delivery of insulin through the Kaleido pump.

"The promising results from the launch of our Kaleido insulin
patch pump in the Netherlands has confirmed that we're filling a gap
in the insulin pump market," said Michael Graves, CEO of ViCentra.
"Our team has developed a unique and innovative product that
addresses a very real need for choice, discretion and simplicity in
the insulin pump market. We believe in a future where closed loop
systems will become a part in diabetes management and we believe that
Kaleido can be an important part of this."

Erik Huneker, founder and co-CEO of Diabeloop adds, "DBLG1 System
is a true revolution, decreasing the burden of managing type 1
diabetes while lowering both time spent in hypoglycemia and the risk
of complications. Combined with the size, convenience and reliability
of the Kaleido pump, it will give back freedom and peace of mind to
people living with type 1 diabetes."

About Diabeloop SA

- Creation: 2015, in Grenoble by Erik Huneker and Dr Charpentier.
Diabeloop and CEA-Leti work within a joint research laboratory to
accelerate product development. The company is co-managed by Marc
Julien and Erik Huneker
- Overall size: 50 people in March 2019
- Funding: 13,5 million euros first funding round in summer 2017.
Second funding round is ongoing

About ViCentra

ViCentra was founded in 2013 with investments from INKEF Capital
and Health Innovations. A further investment was made by LSP in 2016.

Based in the Netherlands, ViCentra believes that if healthcare
products are simple to understand, beautiful to look at and deliver
superb results, they are more enjoyable to use and more likely to
help people achieve great things. ViCentra are creating healthcare
products with this philosophy firmly in mind. They don't design for
patients - they design for people. ViCentra's first product is
Kaleido, a game-changing insulin delivery system for people living
with Type 1 diabetes. More information about ViCentra can be found at
www.ViCentra.com.

Logo: https://mma.prnewswire.com/media/848436/ViCentra_Logo.jpg

Logo: https://mma.prnewswire.com/media/799209/Diabeloop_Logo.jpg

ots Originaltext: Diabeloop; ViCentra
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Press contact Diabeloop: PRPA: Isabelle Closet
Tel: +33(0)1-77-35-60-95
Mail: isabelle.closet@prpa.fr
Diabeloop: Stéphanie Jégu
stephanie.jegu@diabeloop.fr
Press contact Kaleido: Nyxeon: Alexandra Sampson
Tel: +44(0)207-167-2207
Mail: alexandra.sampson@nyxeon.com
ViCentra: Stuart Welland
stuart.welland@vicentra.com

Original-Content von: Diabeloop; ViCentra, übermittelt durch news aktuell